Last $91.72 USD
Change Today +1.98 / 2.21%
Volume 434.5K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Akshay K. Vaishnaw M.D., Ph.D.

Chief Medical Officer and Executive Vice President, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 17 board members in 2 different organizations across 3 different industries.

See Board Relationships
51$1,747,846
As of Fiscal Year 2013

Background*

Dr. Akshay K. Vaishnaw, MD, Ph.D., has been Chief Medical Officer of Alnylam Pharmaceuticals, Inc. since June 13, 2011 and has been its Executive Vice President since June 27, 2012. Dr. Vaishnaw served as Senior Vice President of Clinical Research at Alnylam Pharmaceuticals, Inc. from December 2008 to June 13, 2011 and served as its Senior Vice President from June 13, 2011 to June 27, 2012. Previously, Dr. Vaishnaw served as a Vice President of Clinical Research of Alnylam ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

2014-Present
Director

Education*

MBA
Harvard Business School
PhD
University Of London
MD
University Of Wales College Of Medicine
MD
University of Wales School of Medicine

Other Affiliations*

Annual Compensation*

Salary$450,000
Total Annual Compensation$450,000

Stock Options*

All Other Compensation$7,596
Exercised Options60,980
Exercised Options Value$2,399,785
Exercisable Options202,745
Unexercisable Options135,000
Total Value of Options$2,399,785
Total Number of Options431,225

Total Compensation*

Total Annual Cash Compensation$699,471
Total Short Term Compensation$450,000
Other Long Term Compensation$7,596
Total Calculated Compensation$1,747,846
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $91.72 USD +1.98

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
George W. Hebard III, M.B.AInterim Principal Executive Officer, Interim Chief Operating Officer and Secretary
Enzon Pharmaceuticals Inc.
$428.5K
Hans G. C. P. Schikan Chief Executive Officer and Member of Management Board
Prosensa Holding N.V.
--
Mark W. Schwartz Ph.D.Chief Executive Officer and President
Galena Biopharma, Inc.
$490.0K
Mark J. Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.